OPXA Key Stats
- OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Yahoo 02/28 06:04 ET
- OPEXA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Yahoo 02/27 18:42 ET
- OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Yahoo 02/27 18:42 ET
- Opexa Therapeutics Reports Year End 2013 Financial Results and Provides Corporate Update noodls 02/27 17:28 ET
- Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2013 Financial Results noodls 02/26 10:05 ET
- Opexa Therapeutics, Inc. (OPXA) Active, Shares Gain Street Insider 02/25 13:00 ET
- Will Opexa Become A Multi-Bagger? Yahoo 02/21 12:19 ET
- Opexa Therapeutics CEO to Present at the 2014 Leerink Global Healthcare Conference noodls 02/11 16:46 ET
- Opexa Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference Business Wire 01/29 09:00 ET
- Opexa Therapeutics Chief Scientific Officer Invited as Guest Speaker at the Phacilitate Cell & Gene Therapy Forum Business Wire 01/23 09:00 ET
OPXA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Opexa Therapeutics is up 7.23% over the last year vs S&P 500 Total Return up 24.45%, ARCA biopharma down 20.00%, and Xencor up N/A.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for OPXA
Pro Strategies Featuring OPXA
Did Opexa Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Texas
- Incorporation Country: United States
- Incorporation State/Province: Texas
Opexa Therapeutics, Inc., is engaged in developing personalized cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS). These therapies are based on the proprietary T-cell technology.